Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : G7 urged to donate 'emergency' supplies to vaccine-sharing scheme

05/17/2021 | 06:18am EDT
FILE PHOTO: Vials labelled

GENEVA (Reuters) - The head of UNICEF on Monday asked G7 countries to donate supplies to the COVAX vaccine-sharing scheme as an emergency measure to address a severe shortfall caused by disruption to Indian vaccine exports.

India has curbed exports of the AstraZeneca vaccine made by its Serum Institute, which had been pledged to COVAX, to be used by the country as it battles a massive second wave of infections.

U.N. agency UNICEF, which is in charge of supplying coronavirus vaccines through COVAX, estimates the supply shortfall at 140 million doses by the end of May and about 190 million by the end of June.

"Sharing immediately available excess doses is a minimum, essential and emergency stop-gap measure, and it is needed right now," said UNICEF Executive Director Henrietta Fore, adding that this could help to prevent vulnerable countries from becoming the next global hotspot.

As G7 leaders prepare to meet in Britain next month, the head of the World Health Organization last week denounced the "moral catastrophe" of vaccine inequity, urging wealthy countries to donate doses rather than use them for children who are less vulnerable to severe disease.

Citing new research from scientific information and analytics company Airfinity, UNICEF's Fore said that G7 countries could donate about 153 million doses if they shared only 20% of their available supply over June, July and August.

This could be done while still meeting commitments to vaccinate their own populations, she said without providing further detail.

COVAX, run jointly by the WHO and the GAVI vaccine alliance, relies heavily on the AstraZeneca shot, which accounts for the bulk of the vaccines earmarked for early rollout as it seeks to provide 2 billion doses this year.

UNICEF said that other manufacturing limitations outside India had also slowed supply of COVAX doses but those delays are expected to be resolved by the end of June.

(Reporting by Emma Farge; Editing by David Goodman)

By Emma Farge


© Reuters 2021
All news about ASTRAZENECA PLC
03:04pTHE LATEST : Thousands of vaccines set to expire in Romania
AQ
12:47pWH Smith moves to pacify investors angered over executive pay
RE
12:36pASTRAZENECA  : Swiss health ministry data shows vaccinated people seldom hit by ..
RE
11:48aASTRAZENECA  : EU slightly cuts estimates for vaccine deliveries this year
RE
10:47aWHO estimates COVID-19 boosters needed yearly for most vulnerable
RE
10:06aASTRAZENECA  : 30 Covid-19 Deaths in Kenya as 622 New Cases Posted
AQ
06:46aDOW JONES FXCM DOLLAR INDEX  : NAB on Updated Australia's COVID-19 Vaccine Suppl..
MT
04:58aFTSE 100 rises on dovish BoE; miners, pharma stocks lead gains
RE
04:46aASTRAZENECA  : Secures Conditional Chinese Approval for Lynparza in Prostate Can..
MT
02:20aASTRAZENECA  : Merck & Co's Prostate Cancer Drug Wins Conditional Nod in China
MT
More news
Financials (USD)
Sales 2021 30 988 M - -
Net income 2021 4 559 M - -
Net Debt 2021 10 731 M - -
P/E ratio 2021 26,5x
Yield 2021 3,39%
Capitalization 110 B 154 B -
EV / Sales 2021 3,91x
EV / Sales 2022 3,36x
Nbr of Employees 76 100
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 84,15 $
Average target price 132,57 $
Spread / Average Target 57,5%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC13.63%152 565
JOHNSON & JOHNSON3.34%428 269
ROCHE HOLDING AG10.19%321 632
PFIZER, INC.6.09%218 590
NOVARTIS AG1.55%207 926
ABBVIE INC.6.39%201 349